ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,22
-1,51%
Dow Jones
42 732,13
0,80%
DAX
19 906,08
-0,49%
Brent Oil
76,495
0,00%
Bitcoin
97 688,85
-0,52%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Spyre Therapeutics Inc (SYRE) Cours

Spyre Therapeutics Inc

Spyre Therapeutics Inc (SYRE)

NASDAQ
24,35
0,50
(2,10%)
Fermé 05 Janvier 10:00PM
Retardé de 15 minutes
24,35
0,06
(0,25%)
Après les heures de négociation: 11:00PM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
24,35
Prix Achat
0,94
Prix Vente
24,50
Volume échangé
214 933
23,66 Fourchette du Jour 24,83
18,54 Plage de 52 semaines 47,97
Cap du marché
1,252B
Clôture Veille
23,85
Ouverture
23,66
Dernière Transaction
811
@
24.35
(priorref)
Dernière heure de transaction
Volume financier
US$ 5 228 376
VWAP
24,3256
Volume moyen (3 m)
563 515
Actions en circulation
51 431 220
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-1,82
Bénéfice par action (BPA)
-6,59
Chiffre d'affairess
886k
Bénéfice net
-338,79M

À propos de Spyre Therapeutics Inc

Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an e... Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.spyre.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Spyre Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker SYRE. Le dernier cours de clôture d'Spyre Therapeutics était de US$23,85. Au cours de la dernière année, les actions de Spyre Therapeutics ont été négociées dans une fourchette de prix de US$ 18,54 à US$ 47,97.

Spyre Therapeutics compte actuellement 51 431 220 actions en circulation. La capitalisation boursière d'Spyre Therapeutics est de US$1,23 milliard. Spyre Therapeutics a un ratio cours/bénéfice (ratio PE) de -1.82.

SYRE Dernières nouvelles

Plus de nouvelles

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Jan. 3, 2025 WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the...

03 Janvier 2025
PR Newswire (US)

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Spyre Therapeutics Added to the Nasdaq Biotechnology Index PR Newswire WALTHAM, Mass., Dec. 18, 2024 WALTHAM, Mass., Dec. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a...

18 Décembre 2024
PR Newswire (US)

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Dec. 2, 2024 WALTHAM, Mass., Dec. 2, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the...

02 Décembre 2024
PR Newswire (US)

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies PR Newswire WALTHAM, Mass., Dec. 2, 2024 Spyre is concurrently advancing...

02 Décembre 2024
PR Newswire (US)

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference PR Newswire WALTHAM, Mass., Nov. 25, 2024 WALTHAM, Mass., Nov. 25, 2024 /PRNewswire/ -- Spyre Therapeutics...

25 Novembre 2024
PR Newswire (US)

Form 8-K - Current report

19 Novembre 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

19 Novembre 2024
Edgar (US Regulatory)

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock PR Newswire WALTHAM, Mass., Nov. 18, 2024 WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics...

19 Novembre 2024
PR Newswire (US)

Form 424B5 - Prospectus [Rule 424(b)(5)]

18 Novembre 2024
Edgar (US Regulatory)

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants PR Newswire WALTHAM, Mass., Nov. 18, 2024 WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre...

18 Novembre 2024
PR Newswire (US)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.351.458333333332424.4522.3742478523.35277864CS
4-1.42-5.5102832751325.7727.63522.3748454424.32692313CS
12-2.86-10.510841602427.2140.2622.3756351529.06127261CS
26-0.06-0.2458009012724.4140.2622.3752499428.62354474CS
522.812.993039443221.5547.9718.5450579829.825328CS
15613.54125.2543940810.8147.9710.4247446929.50822971CS
26013.54125.2543940810.8147.9710.4247446929.50822971CS

SYRE - Frequently Asked Questions (FAQ)

What is the current Spyre Therapeutics share price?
The current share price of Spyre Therapeutics is US$ 24,35
How many Spyre Therapeutics shares are in issue?
Spyre Therapeutics has 51 431 220 shares in issue
What is the market cap of Spyre Therapeutics?
The market capitalisation of Spyre Therapeutics is USD 1,23B
What is the 1 year trading range for Spyre Therapeutics share price?
Spyre Therapeutics has traded in the range of US$ 18,54 to US$ 47,97 during the past year
What is the PE ratio of Spyre Therapeutics?
The price to earnings ratio of Spyre Therapeutics is -1,82
What is the cash to sales ratio of Spyre Therapeutics?
The cash to sales ratio of Spyre Therapeutics is 698,26
What is the reporting currency for Spyre Therapeutics?
Spyre Therapeutics reports financial results in USD
What is the latest annual turnover for Spyre Therapeutics?
The latest annual turnover of Spyre Therapeutics is USD 886k
What is the latest annual profit for Spyre Therapeutics?
The latest annual profit of Spyre Therapeutics is USD -338,79M
What is the registered address of Spyre Therapeutics?
The registered address for Spyre Therapeutics is 1521 CONCORD PIKE, SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19803
What is the Spyre Therapeutics website address?
The website address for Spyre Therapeutics is www.spyre.com
Which industry sector does Spyre Therapeutics operate in?
Spyre Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
FCUVFocus Universal Inc
US$ 0,9499
(174,93%)
260,93M
NITON2OFF Inc
US$ 2,6306
(145,85%)
358,28M
CRNCCerence Inc
US$ 19,33
(143,76%)
161,8M
KITTNauticus Robotics Inc
US$ 3,8249
(140,56%)
104,8M
ACONAclarion Inc
US$ 0,2984
(110,14%)
305,64M
HWHHWH International Inc
US$ 0,4621
(-28,80%)
7,08M
SMSTDefiance Daily Target 2x Short MSTR ETF
US$ 5,69
(-26,30%)
24,62M
RAINRain Enhancement Technologies Holdco Inc
US$ 5,59
(-23,42%)
155,16k
PTLEPTL Ltd
US$ 9,35
(-23,30%)
967,95k
NXUNXU Inc
US$ 0,725868
(-22,78%)
7,4M
NITON2OFF Inc
US$ 2,6306
(145,85%)
350,92M
TGLTreasure Global Inc
US$ 0,382
(101,58%)
330,82M
ACONAclarion Inc
US$ 0,2984
(110,14%)
305,59M
FCUVFocus Universal Inc
US$ 0,9499
(174,93%)
259,78M
NVDANVIDIA Corporation
US$ 144,47
(4,45%)
222,72M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
SYRE
Spyre Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés